Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/2028
Full metadata record
DC FieldValueLanguage
dc.contributorLee, B.en_US
dc.contributorGately, L.en_US
dc.contributorLok. S.en_US
dc.contributorTran, B.en_US
dc.contributorLee. M.en_US
dc.contributorWong, R.en_US
dc.contributorMarkman, B.en_US
dc.contributorDunn, K.en_US
dc.contributorWong, Vanessaen_US
dc.contributorLoft, M.en_US
dc.contributorJalili, A.en_US
dc.contributorAnton, A.en_US
dc.contributorTo, R.en_US
dc.contributorAndrews, M.en_US
dc.contributorGibbs, P.en_US
dc.date.accessioned2022-12-16T02:48:49Z-
dc.date.available2022-12-16T02:48:49Z-
dc.date.issued2022-
dc.identifier.govdoc01956en_US
dc.identifier.urihttp://hdl.handle.net/11054/2028-
dc.description.abstractAbstract Traditional cancer registries have often been siloed efforts, established by single groups with limited objectives. There is the potential for registry data to support a broad range of research, audit and education initiatives. Here, we describe the establishment of a series of comprehensive cancer registries across the spectrum of common solid cancers. The experience and learnings of each registry team as they develop, implement and then use collected data for a range of purposes, that informs the conduct and output of other registries in a virtuous cycle. Each registry is multi-site, multi-disciplinary and aims to collect data of maximal interest and value to a broad range of enquiry, which would be accessible to any researcher with a high-quality proposal. Lessons learnt include the need for careful and continuous curation of data fields, with regular database updates, and the need for a continued focus on data quality. The registry data as a standalone resource has supported numerous projects, but linkage with external datasets with patients in common has enhanced the audit and research potential. Multiple projects have linked registry data with matched tissue specimens to support prognostic and predictive biomarker studies, both validation and discovery. Registry-based biomarker trials have been successfully supported, generating novel and practice-changing data. Registry-based clinical trials, particularly randomised studies exploring the optimal use of available therapy options are now complementing the research conducted in traditional clinical trials. More recent projects supported by the registries include health economic studies, personalised patient education material, and increased consumer engagement, including consumer entered data.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2022-11-25T03:27:04Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2022-12-16T02:48:49Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2022-12-16T02:48:49Z (GMT). No. of bitstreams: 0 Previous issue date: 2022en
dc.titleLeveraging comprehensive cancer registry data to enable a broad range of research, audit and patient support activities.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titleCancersen_US
dc.bibliographicCitation.volume14en_US
dc.bibliographicCitation.issue17en_US
dc.bibliographicCitation.stpage4131en_US
dc.subject.healththesaurusCANCER REGISTRYen_US
dc.subject.healththesaurusREGISTRY-BASED TRIALSen_US
dc.subject.healththesaurusDATA-DRIVEN RESEARCHen_US
dc.subject.healththesaurusBIG DATAen_US
dc.subject.healththesaurusDIGITAL HEALTHen_US
dc.identifier.doihttps://doi.org/10.3390/cancers14174131en_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.